Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors 

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.

QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Clinical

Video Series

Additional Second-Line Treatments for HCC

Videos

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Examining the Role of Liver Function in HCC

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

HCC Staging: Improving Treatment Strategies

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Locoregional Therapies for Intermediate-Stage HCC

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients. 

Emerging Therapies in Intermediate-Stage HCC 

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma. 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

The panelists discuss factors that may preclude patients from receiving certain therapies, such as cardiovascular comorbidities, which may pose an immediate threat to the patient's life.

Comorbidity Considerations for HCC Treatment

Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.

The Evolving Landscape of Second-Line Therapies in HCC Management

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma. 

Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma. 

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.

Additional Second-Line Treatments for HCC

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Latest Conference Coverage